• Photo by Megan Jerrad / Visit Faroe Islands

Speakers

Alicia Edin

MD. Department of Clinical Microbiology and the Laboratory for Molecular Infection Medicine Sweden, Umeå University.
Alicia Edin is a PhD student at the department of Clinical Microbiology and a resident physician in anaesthesiology and intensive care at Norrlands University Hospital. Her research interest lies in the field diagnostic methods for infectious diseases, specifically development and validation of molecular methods, diagnostic and prognostic markers. She has worked with validation of qPCR assays for community-acquired pneumonia (CAP) and translational projects for discovery of metabolite markers and increased understanding of infection biology through a metabolomics’ approach. Current projects include lipid profiling in CAP and lipid treatment of sepsis in a large animal model.

 

Anders Fomsgaard, MD DMSc Chief of Lab

Chief Virus R&D, Statens Serum Institut, Copenhagen and ajunct professor Clinical Institut, University of Southern Denmark
Anders Fomsgaard is MD and DMSc from Copenhagen University, adjunct professor in Infectious Diseases at the Infectious Disease Research Unit, Clinical Institute at University of Southern Denmark (SDU) and Chief of Virus R&D BSL3 Laboratory, Statens Serum Institut (SSI), Copenhagen, Denmark. He is author on more than 180 papers and patents in infectious diseases, molecular virology and immunology. Today his main research interest is in HIV-Therapeutic vaccines (cure research), DNA vaccines against influenza and emerging viral diseases as well as development of novel molecular diagnostic methods for virus (microarray, NGS, Lamp etc).

Anders Johansson

MD, PhD. Department of Clinical Microbiology and the Laboratory for Molecular Infection Medicine Sweden, Umeå University; and Department of Infection Control and Prevention, Norrlands University Hospital

Anders Johansson is Associate Professor in Infectious Diseases at Umeå University. He is the Head of the Department of Infection Control and Prevention, Norrlands University Hospital. His research interests include new approaches to diagnose infection using metabolomics, antimicrobial resistance, and infectious diseases epidemiology. Dr. Johansson’s research team and international collaborators have worked extensively on the epidemiology and ecology of the zoonotic disease tularemia, which is caused by the highly virulent bacterium Francisella tularensis. In a worldwide context, the Nordic countries Finland, Sweden and Norway reports top incidence rates of this disease. 

Anna J. Henningsson

MD, PhD. Clinical Microbiology, Region Jönköping County, Sweden

Anna J. Henningsson, MD, PhD, is a specialist in infectious diseases and clinical microbiology. She has pursued research in the field of tick-borne diseases in close collaboration with Linköping University for over ten years. Her main focus is clinical, diagnostic, epidemiological and immunological aspects of Lyme borreliosis. She is part of several collaboration projects concerning tick-borne diseases and involving physicians and researchers in the Nordic countries, and she is one of the contact persons for the NSCMID TBD working group.

Anu Kantele

MD PhD, Professor of Infectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Anu Kantele is Professor of Infectious Diseases at the University of Helsinki, Finland and Visiting Professor at the Karolinska Institutet, Sweden. In addition, she functions as Senior Medical Officer at the Helsinki University Hospital and heads the Travel Clinic at Medical Centre Aava in Helsinki. Her research interests include various areas within infectious diseases such as travel medicine, tropical diseases, antibiotic resistance, diarrhoea, immunology and vaccines.   

Björn Herrmann

PhD, Associate professor in Clinical microbiology at Akademiska Sjukhuset, Uppsala, Sweden.

Research in Chlamydia infections, mainly diagnostics and epidemiology of sexually transmitted C. trachomatis. Also zoonotic C. psittaci infections in birds and humans and other bacteria causing respiratory tract infections.

Title of speech: Chlamydia psittaci and psittacosis – A thrilling story from the Faroe Islands

Brian J. McMahon

MD, MACP, FAASLD, Medical and Research Director, Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, 4315 Diplomacy Drive, Anchorage, AK 99508, And Research Associated, Arctic Investigations Program, Centers for Disease Control and Prevention, Auxiliary Professor of Health Sciences, University of Alaska, Anchorage, Clinical Associate Professor of Medicine, University of Washington, Seattle

Brian J. McMahon MD is a clinical Hepatologist who directs an Alaska-wide program caring for over 1200 Alaska Natives with chronic hepatitis B and 2400 with chronic hepatitis C. He conducts research on long-term protection of hepatitis A and B vaccines as well as on the outcome and management of chronic hepatitis B and C.

He was the co author of the AASLD Practice Guideline on Chronic Hepatitis B 2001 to 2009, on the methodology committee for the 2016 AASLD Guidelines and the writing committee for the 2017 AASLD supplemental Guideline. He was co-chair of the WHO hepatitis B Guidelines Committee. 

Carsten Schade Larsen

Senior medical Consultant, associate professor. MD, DMSc. Department of Infectious Diseases, Aarhus University Hospital, Denmark

Carsten Schade Larsen is Director of International Center for Immunodeficiencies, Site-Director GeoSentinel Center Aarhus and Member of the Steering Group of the Danish HIV Cohort Study. His main research fields are primary immunodeficiencies, hiv-infection and travel medicine

Christian G. Giske

MD/PhD, Associate professor/Senior consultant physician in Clinical microbiology. Karolinska Institute and Karolinska University Hospital

Christian G. Giske is the current chairman of the European Committee on Antimicrobial Susceptibility Testing and a research group leader at Karolinska Institutet. His main interests are antimicrobial susceptibility testing, as well as resistance mechanisms and molecular epidemiology of multi drug-resistant Gram-negative pathogens such as E. coli, K. pneumoniae and P. aeruginosa. The group of Giske also focuses on translation approaches to understand the importance of bacterial factors such as clonality and virulence for patient outcomes. Moreover, the group has an interest in microbiota characterisation and generally employ next-generation sequencing as a major research tool.

Christoph Lange

Research Center Borstel and University of Lübeck, Germany; Karolinska Institute, Stockholm, Sweden

Chistoph Lange is Professor of International Health/Infectious Diseases at the University of Lübeck, Germany.  He is Chief attending physician at the Medical Clinic of the Research Center Borstel (FZB),Head of Clinical Infectious Diseases at the FZB and Head of the Clinical Tuberculosis Center of the German Center for Infection Research (DZIF). His current research activities focus on precision medicine for MDR-TB, especially on biomarkers as early indicators for therapy success or failure and for relapse-free cure. Together with his colleagues he is evaluating the role of comprehensive genotypic drug-resistance testing on the design of antituberculosis drug regimen and of therapeutic drug monitoring to optimize treatment outcomes in MDR-TB.

Elías Sæbjörn Eyþórsson

University of Iceland, Reykjavík, Iceland; Landspítali University Hospital, Reykjavík, Iceland

Elias Eythorsson is a PhD student in the research group Vaccination Study in Iceland (VIce) at Landspítali University Hospital. The aim of his PhD project is to study the effects of the introduction of the 10-valent pneumococcal H. influenzae Protein-D conjugate vaccine into the paediatric vaccination program in Iceland on healthcare consumption. The focus of his PhD will be to use individual level linked whole population registry data to quantify the effect of vaccination on visits for respiratory infections, antibiotic prescription rates, ventilation tube placements and hospital admissions.

Hans Jørn Kolmos 

MD DMSc, Department of Clinical Microbiology, Odense University Hospital & University of Southern Denmark 

Professor of clinical microbiology, University of Southern Denmark (SDU) & chief physician, Department of Clinical Microbiology, Odense University Hospital (OUH). Head of Graduate School of Health Sciences at SDU. Chairman of Infection Control Committee at OUH. Main areas of research: hospital hygiene, device-associated infections, recurrent UTI, MRSA, antibiotic stewardship, antimicrobial activity of non-antibiotics, infection & atherosclerosis.

Title of presentation: Infection Control – in an Era of Multi Drug Resistant Organisms

Heiner Wedemeyer

Prof. Hannover Medical School, Hannover, Germany

Prof. Heiner Wedemeyer leads a research group on cellular immunology and clinical virology at the Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany. Heiner Wedemeyer has been principal investigator in numerous clinical trials, focusing on antiviral therapy and immunotherapy of viral hepatitis B, C, D and E. He has authored over 280 original articles; his current Hirsch-Index is 74 (google scholar). Heiner Wedemeyer is one of the coordinators of the German Hepatitis C Registry and was leading the European Association for the Study of the Liver (EASL) as Secretary General from 2009 to 2011.

Henrik Westh

Professor MD. MRSA KnowledgeCenter, Department of Clinical Microbiology, Hvidovre Hospital, Denmark

The MRSA KnowledgeCenter has a practical research-oriented approach looking at evolution, epidemiology, typing, whole genome sequencing, carriage, characteristics of patients’ illnesses and outcomes, infection-control and eradication therapies. A NGS center has been built up since 2012 focusing on rapid WGS for infection control with new focus areas in viral population studies and shotgun metagenomics on clinical samples.

Hilmir Ásgeirsson, MD, PhD.

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.

Hilmir Asgeirsson is as a specialist in infectious diseases at the Department of Infectious Diseases at Karolinska University Hospital. He works as a clinician, arranges courses on tropical infectious diseases, and is involved in different research projects on bacterial infections and travel medicine. He is the site director for the Stockholm site of GeoSentinel, the Global Surveillance Network of the International Society of Travel Medicine (ISTM) and the Centers for Disease Control (CDC). His main interests are in the field of tropical medicine as well as in severe bacterial infections.

Håkan Hanberger

Professor, senior physician infectious diseases Håkan Hanberger. Division of Infectious Diseases, Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden

Hanberger, is a specialist in infectious diseases, professor at the University of Linköping and chair of Swedish Reference Group of Antibiotics.  He is the leader of a research group studying the epidemiology of antibiotic resistance in low and high income countries. He is interests are in the fields of surviving sepsis, antibiotic stewardship, infection control, mechanisms of antibiotic resistance and interventions against antibiotic resistance.

Isik Somuncu Johansen

Professor, DMSc and senior consultant in Infectious Diseases, Odense University Hospital, Odense, Denmark.

My research has focused on molecular methods in diagnosing tuberculosis and mycobacterial infections, drug resistant tuberculosis, epidemiology and clinical investigation of paediatric tuberculosis and extrapulmonary tuberculosis. Furthermore, I have studied the interplay between HIV and tuberculosis in Ghana.

Jan Gorm Lisby

MD PhD, Chief Physician, Department of Clinical Microbiology, University of Copenhagen, Hvidovre Hospital, Denmark

Dr Lisby´s academic interests are diagnostics and treatment strategies for sepsis, decision support/risk assessment, development of fast diagnostic methods for infectious diseases, point of care diagnostics and health economics. He is the founder of Anapa Biotech, Inc, where he served as CSO from 2007-2013.

Jens D. Lundgren, Professor

Rigshospitalet, University of Copenhagen, Denmark

I am Professor of Viral Diseases and a practicing infectious disease specialist. I founded, and head, CHIP (Centre of Excellence for Health, Immunity and Infections) and PERSIMUNE (Centre of Excellence for Personalised Medicine of Infectious Complications in Immune Deficiency) at the department of infectious diseases, based at the Copenhagen University Hospital (Rigshospitalet), University of Copenhagen.

See www.chip.dk and www.persimune.dk. My primary research interests are clinical and public health aspects of the HIV infection itself, and its infectious and non-infectious associated morbidities.

I chair the WHO Collaborative Centre on HIV and Viral Hepatitis, co-chairs the START study, and I am co-chief-editor of HIV Medicine. I am a member of the Executive Committee of the NIH/NIAID funded INSIGHT network (International Network for Strategic Initiatives in Global HIV Trials) which is conducting the START study, and chair its scientific steering committee.

Laura Puhakka

MD, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Laura Puhakka is a pediatrician and a phD student in a project "Congenital cytomegalovirus infection in Finland". The aim of the study is to learn more about the burden of congenital CMV infection. In the prospective cohort study she is studying the prevalence of cCMV and the outcome of the infected infants.   

Magnus Gottfredsson

MD, PhD, FACP. Professor of Medicine and chief Landspitali University Hospital and Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjvik Iceland

Magnus Gottfredsson is professor of infectious diseases at the School of Health Sciences at the University of Iceland. He is also chief, Department of Science at Landspitali University Hospital and consultant in the Department of infectious diseases. He graduated with MD and PhD degrees from the University of Iceland and specialized in internal medicine and infectious diseases at Duke University Medical Center in North-Carolina, USA. He divides his time between clinical teaching, research and administration. His research interests include pathogenesis of invasive bacterial infections, including meningitis and sepsis, diagnosis and treatment of HIV and hepatitis C, and molecular epidemiology of infectious diseases. 

Olav Dalgard

Overlege, professor, dr.med. Infectious disease department Akershus University Hospital

Olav Dalgard is a professor of infectious diseases at Akershus University Hospital in Norway. His main research interest has been hepatitis C infection in people who inject drugs focusing on natural history of the disease and delivery of care. Mostly recently he has studied reinfection after successful HCV treatment. He is chairing the committees that write HCV and HBV treatment guidelines in Norway and is a member of the public health committee of the European Association for the study of Liver Disease (EASL). He is a member of the board of the International Network on Hepatitis Care in Substance Users (INHSU) 

Marita Debess Magnussen

PhD student at the Medical faculty of University of Iceland, Reykjavík, Iceland

 

Marita is a PhD student interested in antibiotic resistance in the Faroe Islands with a PhD project with the title “Antimicrobial resistance in Streptococcus pneumoniae and Streptococcus pyogenes and Escherichia coli isolates from the Faroese population, correlation with antimicrobial use and comparison with Denmark and Iceland

Michael Bruce

MD, MPH, Epidemiology Team Leader

Michael Bruce is a public health physician and medical epidemiologist trained in Internal and Preventive Medicine. He is the Epidemiology Team Leader at the Centers for Disease Control and Prevention’s Arctic Investigations Program in Alaska, USA. For the past 17 years, his work has focused on improving health in Alaska Native communities, creation of a sentinel surveillance system in Alaska for detecting infection caused by Helicobacter pylori, and setting up, managing and analyzing data from the international circumpolar surveillance (ICS) system for invasive bacterial diseases. He has received numerous awards and has published over 125 scientific articles and book chapters. 

Ole Schmeltz Søgaard

MD PhD. Dept. of Infectious Diseases, Aarhus University Hospital, Denmark

The primary barrier preventing eradication of HIV-infection by combination antiretroviral therapy is a pool of long-lived infected cells. These latently infected cells harbour integrated proviral DNA capable of resuming HIV-expression and fuelling viral rebound in the absence of antiretroviral therapy. However, in the inactive state this persistent viral reservoir is unrecognizable to the immune system and unresponsive to antiretroviral drugs. My area of research is focused on finding a cure for HIV by reactivation of the latent HIV reservoir using small molecules and by developing immunotherapeutic strategies that enhance immunological control of HIV replication.

Robert Skov

MD and specialist in Clinical Microbiology. Since June 2016 he is heading Microbiology at MVZ Synlab Leverkusen, Germany

Prior to that he worked at Statens Serum Institut, Copenhagen the last 6 years as the head of the Bacteriological Surveillance and Infection Control which includes the Staphylococcal Reference Laboratory, Central Unit for Infection Control and the Laboratory for Antimicrobial Surveillance and resistance. He has been a Member of a number of national and international expert groups including for ECDC with focus on epidemiology and control of resistant microorganisms. Between 2005 and 2016 he has been central in the development of the Danish guidelines for MRSA infection control policy. From 2012-2014 he was a member of the Steering Committee European Committee on Antimicrobial Susceptibility Testing (EUCAST). His main research focus is epidemiology, virulence and resistance of S. aureus as well as methodology of antimicrobial resistance detection. 

Sigurður Skarpheðinsson

Senior ID consultant, associate professor. MD, PhD. Department of Infectious Diseases, Odense University Hospital.

Sigurður Skarphéðinsson is  a specialist in infectious diseases, founder  and director of Clinical Center for Emerging and Vector-borne Infections  (CCEVI) at the Department of infectious Diseases, OUH. His primary research interests are vector-borne and zoonotic infections, especially tick-borne infections their epidemiology, clinical and public health aspects and infections of the central nervous system.

Svein-Ole Mikalsen

Dr.philos., Professor, Department of Science and Technology, Faculty of Health and Natural Sciences, University of the Faroe Islands

Svein-Ole Mikalsen is professor in molecular biology at the University of the Faroe Islands. He is broadly interested in molecular biology, and he works with both mass spectrometry (proteins and small molecules) and genetics (DNA sequencing). His present research stretches from evolutionary analysis of gene families via mass spectrometric analysis of peptides and environmental pollutants to metagenomics.

Theresa Maria Wagner

MSc - Research group for Host-microbe Interactions, Department of Medical Biology, UiT – The Arctic University of Norway, Tromsø, Norway

Theresa Wagner is a phd student in the research group for host-microbe interactions at UiT – The Arctic University of Norway. The aim of her phd project is to study molecular determinants involved the interaction between Enterococcus and the host. In particular she is focusing on virulence factors and immune evasion mechanism utilized by E. faecium to overcome innate immune defenses. This knowledge will help a better understanding of invasive properties of Enterococcus, which is needed for basic research as well as in the development of novel prevention and treatment strategies for infectious diseases.

Troels Lillebaek

Director, Consultant, DMSc. International Reference Laboratory of Mycobacteriology, Statens Serum Institut

ID-specialist working/researching nationally and internationally within the area of tuberculosis and mycobacteriology. Especially, molecular epidemiology, genotyping, diagnostics, and TB control.

Ørjan Samuelsen

PhD, Professor, Norwegian National Advisory Unit on Detection of Antimicrobial Resistance, University Hospital of North Norway and Dept. of Pharmacy, UiT The Arctic University of Norway.

Ørjan Samuelsen is a senior scientist at the Norwegian National Advisory Unit on Detection of Antimicrobial Resistance and professor at UiT – The Arctic University of Norway. His main research focus is on antimicrobial resistance in Gram-negative bacteria and in particular β-lactamase-mediated resistance. The research activities cover aspects such as molecular epidemiology, diagnostic methods, biochemical and structural characterization of β-lactamases, β-lactamase inhibitors, in vivo evaluation of treatment options, and the transmission dynamics of resistance plasmids.